Q3 Group LFL net revenue growth of +3.4%
Led by strong broad-based growth across our Hygiene and Health portfolio, which delivered a LFL growth +6.7% on a combined basis. This LFL growth was reduced by a (11.9%) decline in our Nutrition business, reflecting the rebasing of the US IFCN market following the shortage crisis in the prior year.
Growth was broad-based across OTC, Finish, Lysol and our Intimate Wellness portfolios. Within Nutrition, we continue to hold US IFCN market leadership and our brand Enfamil remains the Number One Trusted by Consumers and the Number One Recommended Infant Formula by Paediatricians in the US.
Volume declined (4.3%) on a group basis with improving trends in Hygiene throughout the period, resilient volume delivery in Health, offset by the expected declines in our Nutrition business. Volume declined (1.6%) for Hygiene and Health on a combined basis.
Price / mix grew +7.5% on a group basis, reflecting a combination of carry over pricing, new pricing behind our innovation programme and in markets where the inflationary environment is more pronounced.
Hygiene LFL net revenue growth of +8.1%. Broad-based growth across all core categories, driven by double digit growth in Finish and Vanish.
Health LFL net revenue growth of +5.4%. Growth driven by OTC and Intimate Wellness portfolios. Dettol and VMS were broadly stable.
Nutrition LFL net revenue decline of -11.9%. We maintain market leadership in the US but lap the temporary benefits from competitor supply issues in the prior year.